TL;DR: Aetna, a CVS Health company, modified CPB 1016 for betibeglogene autotemcel (Zynteglo), effective January 5, 2026. Here's what billing teams need to do.
Aetna updated its Zynteglo coverage policy under CPB 1016 Aetna system, tightening the medical necessity criteria for this one-time gene therapy treatment for transfusion-dependent beta-thalassemia. The primary billing code for this therapy is HCPCS J3393 (injection, betibeglogene autotemcel, per treatment), supported by a cluster of CPT codes covering stem cell harvesting, transplant preparation, and infusion administration. If your practice or institution treats beta-thalassemia patients and bills Aetna commercial plans, this policy revision sets the exact bar your prior authorization requests must clear.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Betibeglogene Autotemcel (Zynteglo) |
| Policy Code | CPB 1016 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Stem Cell Transplant Programs, Infusion Centers |
| Key Action | Contact Aetna's National Medical Excellence (NME) team at 877-212-8811 before submitting any precertification for J3393 |
Aetna Betibeglogene Autotemcel (Zynteglo) Coverage Criteria and Medical Necessity Requirements 2026
Aetna's Zynteglo coverage policy covers exactly one dose, total, for transfusion-dependent beta-thalassemia. There is no repeat dosing pathway. If a member received this therapy before, they are not eligible — full stop.
Aetna designates Zynteglo as a GCIT® (Gene-based, Cellular & Other Innovative Therapies) product. That designation matters for your billing team because it routes precertification through a separate channel. Do not submit through standard prior authorization workflows. Call National Medical Excellence (NME) at 877-212-8811.
Age and Weight Requirements
The member must be at least four years old and weigh at least 6 kg. They also must be reasonably expected to produce enough cells to initiate manufacturing. That third requirement is clinical — your hematologist needs to document it explicitly in the precertification request.
A hematologist must prescribe or consult on the case. Aetna will not approve this without that specialty involvement documented.
Transfusion Burden Threshold
The member must have a confirmed diagnosis of transfusion-dependent beta-thalassemia — either non-β0/β0 or β0/β0 genotype — confirmed by genetic testing. Document the specific genotype. Vague diagnoses will slow or kill your prior authorization.
Within the previous two years, the member must meet one of two transfusion thresholds:
| # | Covered Indication |
|---|---|
| 1 | At least 100 mL/kg of packed red blood cells (pRBCs) per year, or |
| 2 | At least eight transfusion events of pRBCs per year |
One threshold is enough. But you need documented transfusion history. Pull those records before you submit the precertification request.
Transplant Eligibility Requirement
The member must be eligible for a hematopoietic stem cell transplant (HSCT) but unable to find a matched 10/10 HLA-related donor. This is a meaningful filter. Aetna is not approving Zynteglo for patients who simply prefer gene therapy over transplant. The matched donor search must have happened and failed.
Document the failed donor search in the chart. Without that, expect a denial.
Prior Treatment Exclusions
The member cannot have received a prior HSCT. They also cannot have received Zynteglo or any other gene therapy. This is a one-shot therapy — literally and from a coverage policy standpoint.
Medical Conditions That Disqualify the Member
Aetna disqualifies members with any of the following conditions. Review this list before submitting — a single disqualifying condition ends the coverage determination:
| # | Covered Indication |
|---|---|
| 1 | Severe iron overload (T2*-weighted MRI of myocardial iron < 10 msec) |
| 2 | HIV-1 or HIV-2 positive status |
| 3 | Hepatitis B or Hepatitis C positive status |
| 4 | Any prior or current malignancy (ICD-10 C00.0–C96.Z) |
| 5 | Advanced liver disease — bridging fibrosis, cirrhosis, or active hepatitis (ICD-10 K70.0–K77) |
| 6 | Uncorrected bleeding disorder |
| 7 | Myeloproliferative and/or immunodeficiency disorder |
| 8 | Uncontrolled seizure disorder (ICD-10 G40.001–G40.C19) |
| 9 | Renal impairment with creatinine clearance ≤ 70 mL/min/1.73 m² |
The ICD-10 codes for these exclusions matter. If any of these codes appear on the patient's problem list or claims history, Aetna's reviewers will flag them. Make sure your documentation explains current status — for example, if hepatitis C was treated and resolved, document that clearly with current lab values.
Network Requirement
Unless the member's health plan has opted out, Zynteglo must be administered at an Aetna Institutes® GCIT Designated Network facility. Check the current facility list at Aetna's site before scheduling the infusion. Administering at a non-designated facility is a fast path to claim denial and potential balance billing exposure.
Aetna Zynteglo Exclusions and Non-Covered Indications
Aetna's position is direct: all indications outside the specific criteria above are experimental, investigational, or unproven.
That includes off-label use of betibeglogene autotemcel for any condition other than transfusion-dependent beta-thalassemia, and any use in patients who do not meet every single criterion listed. This is an AND-based coverage policy — all criteria must be met simultaneously. Meeting six of seven criteria still produces a denial.
If you're treating a patient who almost qualifies — say, a member who had a prior HSCT — there is no appeal path that will change the medical necessity determination. The policy is explicit.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Transfusion-dependent beta-thalassemia (non-β0/β0 or β0/β0), age ≥4, weight ≥6 kg, ≥100 mL/kg pRBCs/year OR ≥8 transfusion events/year, no matched HLA donor, no prior HSCT or gene therapy, no disqualifying conditions | Covered — One Dose Total | J3393, D56.1 | Prior auth through NME required; GCIT network facility required |
| Any other indication for betibeglogene autotemcel | Not Covered — Experimental/Investigational | J3393 | All criteria must be met; partial qualification is not sufficient |
| Repeat dosing of Zynteglo | Not Covered | J3393 | Policy covers one dose total, lifetime |
| Patients with prior HSCT | Not Covered | J3393, 38240, 38241 | Explicit exclusion in criteria |
| Patients with active HIV, HBV, or HCV | Not Covered | J3393 | Refer to ICD-10 B16.x, B17.10, B17.11, B20, B97.35 |
| Patients with any current or prior malignancy | Not Covered | J3393 | Refer to ICD-10 C00.0–C96.Z |
| Patients with severe iron overload (T2* MRI myocardial iron < 10 msec) | Not Covered | J3393 | Refer to ICD-10 E83.110–E83.119 |
| Patients with advanced liver disease | Not Covered | J3393 | Refer to ICD-10 K70.0–K77 |
| Patients with renal impairment (CrCl ≤70 mL/min/1.73 m²) | Not Covered | J3393 | Refer to ICD-10 N17, N18, N19 |
Aetna Zynteglo Billing Guidelines and Action Items 2026
This therapy is not your standard infusion claim. Betibeglogene autotemcel billing touches stem cell collection, manufacturing coordination, transplant preparation, and infusion — across multiple CPT codes and likely multiple facility encounters. Here's how to manage it.
| # | Action Item |
|---|---|
| 1 | Route precertification through NME, not standard prior authorization. Call 877-212-8811 before any other step. Do this before the effective date of January 5, 2026, if you have any pending cases. Standard prior auth workflows will not work here. |
| 2 | Verify GCIT network status for your administration site. Check Aetna's GCIT Designated Network list now. If your facility is not listed, the claim will be denied regardless of clinical eligibility. Don't assume — confirm in writing. |
| 3 | Collect and attach the full transfusion history. You need two years of transfusion records showing either ≥100 mL/kg pRBCs/year or ≥8 transfusion events/year. Build a documentation checklist that your clinical team completes before the precertification package goes to NME. |
| 4 | Document the failed matched donor search explicitly. The 10/10 HLA-matched donor search must be on record and must have failed. A notation in the chart that says "no matched donor available" is not sufficient. Get the formal search results documented. |
| 5 | Screen for all disqualifying conditions before submitting. Run the member's chart against the eight disqualifying conditions in the policy. If any appear in the problem list, resolve the documentation question first. For conditions like treated hepatitis C, include current lab values showing resolution. |
| 6 | Assign the correct codes for each phase of treatment. Stem cell harvesting bills under CPT 38205 or 38206. Transplant preparation — cryopreservation, thawing, cell concentration — maps to CPT 38207, 38208, 38209, and 38215. The infusion itself bills under J3393, supported by CPT 96365–96368 or 96413–96415 depending on your administration context. Get your charge capture set up for each phase now, before you have an active case moving through the workflow. |
| 7 | Flag any claims with disqualifying ICD-10 codes. If the patient's record includes codes from C00.0–C96.Z (malignancy), B20 (HIV), B16.x or B17.10–B17.11 (hepatitis), E83.110–E83.119 (iron overload), G40.001–G40.C19 (seizures), K70.0–K77 (liver disease), or N17–N19 (renal impairment), that is a disqualifying condition. Build a hard stop in your precertification workflow. |
| 8 | Talk to your compliance officer before billing for the conditioning regimen. The myeloablative conditioning chemotherapy that precedes Zynteglo infusion bills separately under CPT 96413–96415. Reimbursement for conditioning is a separate coverage question from the gene therapy itself. Don't assume it's bundled, and don't assume it's automatically approved. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Betibeglogene Autotemcel (Zynteglo) Under CPB 1016
HCPCS Code — Primary Billing Code for Zynteglo
| Code | Type | Description |
|---|---|---|
| J3393 | HCPCS | Injection, betibeglogene autotemcel, per treatment |
CPT Codes — Transfusion, Stem Cell Processing, and Infusion Administration
| Code | Type | Description |
|---|---|---|
| 36430 | CPT | Transfusion, blood or blood components |
| 36440 | CPT | Push transfusion, blood, 2 years or younger |
| 36450 | CPT | Exchange transfusion, blood; newborn |
| 36455 | CPT | Exchange transfusion, blood; other than newborn |
| 36456 | CPT | Partial exchange transfusion, blood, plasma or crystalloid necessitating the skill of a physician |
| 38205 | CPT | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic |
| 38206 | CPT | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous |
| 38207 | CPT | Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage |
| 38208 | CPT | Transplant preparation; thawing of previously frozen harvest, without washing, per donor |
| 38209 | CPT | Transplant preparation; thawing of previously frozen harvest, with washing, per donor |
| 38215 | CPT | Transplant preparation; cell concentration in plasma, mononuclear, or buffy coat layer |
| 38240 | CPT | Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor |
| 38241 | CPT | Hematopoietic progenitor cell (HPC); autologous transplantation |
| 96365 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
| 96366 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
| 96367 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; additional sequential infusion |
| 96368 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; concurrent infusion |
| 96413 | CPT | Chemotherapy administration, intravenous infusion technique; up to 1 hour |
| 96414 | CPT | Chemotherapy administration, intravenous infusion technique; each additional hour |
| 96415 | CPT | Chemotherapy administration, intravenous infusion technique; each additional sequential infusion |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| D56.1 | Beta thalassemia — primary covered diagnosis |
| B16.0–B16.9 | Acute hepatitis B — disqualifying condition |
| B17.10 | Acute hepatitis C without hepatic coma — disqualifying condition |
| B17.11 | Acute hepatitis C with hepatic coma — disqualifying condition |
| B20 | Human immunodeficiency virus [HIV] disease — disqualifying condition |
| B97.35 | HIV-2 as the cause of diseases classified elsewhere — disqualifying condition |
| C00.0–C96.Z | Neoplasms — disqualifying condition (any prior or current malignancy) |
| D66 | Hereditary factor VIII deficiency — related bleeding disorder |
| E83.110–E83.119 | Hemochromatosis/iron overload — disqualifying condition |
| G40.001–G40.C19 | Epilepsy and recurrent seizures — disqualifying condition (uncontrolled) |
| K70.0–K77 | Disease of liver — disqualifying condition (advanced liver disease) |
| N17 | Acute kidney failure — disqualifying condition |
| N18 | Chronic kidney disease — disqualifying condition |
| N19 | Unspecified kidney failure — disqualifying condition |
| Z20.6 | Contact with/suspected exposure to HIV — relevant screening code |
| Z21 | Asymptomatic HIV infection status — disqualifying condition |
Get the Full Picture for CPT 38205
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.